CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / ELI Lilly & CO (LLY) / imlunestrant
Forward catalyst · LLY

imlunestrant

Sponsor ELI Lilly & CO · listed as LLY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

imlunestrant is a clinical-stage drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 2027 (month precision, medium confidence), tied to trial NCT05514054. The asset is in Phase 3 and currently active not recruiting, studied in Breast Neoplasms. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-10-31
As disclosedOct 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05514054
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorEli Lilly and Company
Listed asLLY
Condition(s)Breast Neoplasms
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More LLY catalysts

Related catalysts and sponsor